{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:09:43Z","timestamp":1792206583187,"version":"4.4.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022344","name":"InflaRx GmbH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022344","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The results of a previous phase IIa trial suggested efficacy of the anti-C5a compound vilobelimab in a small number of patients with severe hidradenitis suppurativa (HS) refractory to adalimumab treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To study the efficacy of vilobelimab in a larger-scale randomized phase IIb trial (SHINE) of patients with moderate-to-severe HS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In total, 177 patients with moderate-to-severe HS were treated either with placebo or one of four doses of vilobelimab, a monoclonal antibody that targets the complement split product C5a. Hidradenitis Suppurativa Clinical Response (HiSCR) at 16 weeks was the primary endpoint. Those who achieved HiSCR switched to open-label low-dose vilobelimab; those who did not were switched to medium-dose vilobelimab. The trial was registered with the EU Clinical Trials Register (EudraCT number 2017-004501-40) and ClinicalTrials.gov (NCT03487276).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study did not meet the primary endpoint, perhaps due, in part, to an unexpectedly high HiSCR placebo response rate of 47.1%. HS flares decreased and post hoc analysis showed that high-dose vilobelimab significantly decreased the median draining tunnel counts and IHS4 score by 63%. Following the switch to medium-dose vilobelimab at week 16, 45.5% of those who did not respond to treatment achieved HiSCR at week 40.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Compared with placebo, vilobelimab treatment did not result in significant HiSCR improvements in patients with moderate-to-severe HS. Post hoc analysis revealed significant effects for the highest tested dose on draining tunnel reduction and IHS4 score, which captures reductions in draining tunnels. These findings warrant further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf398","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T12:03:22Z","timestamp":1760097802000},"page":"254-263","source":"Crossref","is-referenced-by-count":5,"title":["Vilobelimab to improve clinical outcomes in moderate-to-severe hidradenitis suppurativa through an adjunctive effect on draining tunnels: results of the SHINE double-blind placebo-controlled randomized trial"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4713-3911","authenticated-orcid":false,"given":"Evangelos J","family":"Giamarellos-Bourboulis","sequence":"first","affiliation":[{"name":"4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0712-2540","authenticated-orcid":false,"given":"Gregor B E","family":"Jemec","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zealand University Hospital , Roskilde ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8158-660X","authenticated-orcid":false,"given":"Errol P","family":"Prens","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus University Medical Center , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-3315","authenticated-orcid":false,"given":"Niels\u00a0C","family":"Riedemann","sequence":"additional","affiliation":[{"name":"InflaRx GmbH, Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabell","family":"Otto","sequence":"additional","affiliation":[{"name":"InflaRx GmbH, Jena ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Weisman","sequence":"additional","affiliation":[{"name":"Medical Dermatology Specialists, Sandy Springs, Atlanta, GA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazyna","family":"Pulka","sequence":"additional","affiliation":[{"name":"Centrum Medyczne All-Med , Krak\u00f2w ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4768-1387","authenticated-orcid":false,"given":"Roman J","family":"Nowicki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Medical University of Gda\u0144sk, University Clinical Centre , Gda\u0144sk ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vessel","family":"Kantardjiev","sequence":"additional","affiliation":[{"name":"Dermatology and Venereology Department, Military Medical Academy , Sofia ,","place":["Bulgaria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1330-1502","authenticated-orcid":false,"given":"Andreas","family":"Pinter","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, University Hospital Frankfurt\/Main , Frankfurt\/Main ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-300X","authenticated-orcid":false,"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Copenhagen University Hospital-Bispebjerg and Frederiksberg , Copenhagen ,","place":["Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Berneman","sequence":"additional","affiliation":[{"name":"University of Cincinnati, Department of Dermatology , Cincinnati, OH ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-1556","authenticated-orcid":false,"given":"Theodora","family":"Kanni","sequence":"additional","affiliation":[{"name":"4th Department of Internal Medicine, National and Kapodistrian University of Athens, Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1171-4917","authenticated-orcid":false,"given":"Afsaneh","family":"Alavi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Mayo Clinic Rochester , Rochester, MN ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Breno","sequence":"additional","affiliation":[{"name":"CHU Nantes, H\u00f4tel Dieu, Nantes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8926-0113","authenticated-orcid":false,"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"SKiN Centre for Dermatology , Peterborough, ON ,","place":["Canada"]},{"name":"Department of Medicine , Queen\u2019s University, Kingston, ON ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Stone","sequence":"additional","affiliation":[{"name":"Shenandoah Medical Center , Shenandoah, IA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-3953","authenticated-orcid":false,"given":"Milan J","family":"Anadkat","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Dermatology, Washington University , St. Louis, MO ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8189-7486","authenticated-orcid":false,"given":"Alexandros","family":"Katoulis","sequence":"additional","affiliation":[{"name":"2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-5338-6060","authenticated-orcid":false,"given":"Markos","family":"Papakonstantis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, 401 General Military Hospital of Athens , Athens ,","place":["Greece"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7117-7489","authenticated-orcid":false,"given":"Pierre-Andr\u00e9","family":"Becherel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Antony Private Hospital , Antony ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Wroc\u0142aw University of Science and Technology , Wroc\u0142aw ,","place":["Poland"]},{"name":"Department of Dermatovenereology, 4th Military Hospital , Wroc\u0142aw ,","place":["Poland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2874-7726","authenticated-orcid":false,"given":"Hessel H","family":"van der Zee","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Erasmus University Medical Center , Rotterdam ,","place":["the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1646-2608","authenticated-orcid":false,"given":"Christos C","family":"Zouboulis","sequence":"additional","affiliation":[{"name":"Departments of Dermatology, Venereology, Allergology and Immunology, Staedtisches Klinikum Dessau, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg , Dessau ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3201-4637","authenticated-orcid":false,"given":"Christopher\u00a0J","family":"Sayed","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of North Carolina , Chapel Hill, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2026012706471128200_ljaf398-B1","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1111\/exd.14214","article-title":"What causes hidradenitis suppurativa? 15\u2005years after","volume":"29","author":"Zouboulis","year":"2020","journal-title":"Exp Dermatol"},{"key":"2026012706471128200_ljaf398-B2","doi-asserted-by":"crossref","first-page":"eaav5908","DOI":"10.1126\/scitranslmed.aav5908","article-title":"Neutrophil extracellular traps, B cells, and type I interferons contribute to immune dysregulation in hidradenitis suppurativa","volume":"11","author":"Byrd","year":"2019","journal-title":"Sci Transl Med"},{"key":"2026012706471128200_ljaf398-B3","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.jid.2016.04.021","article-title":"High copy numbers of \u03b2-defensin cluster on 8p23.1, confer genetic susceptibility, and modulate the physical course of hidradenitis suppurativa\/acne inversa","volume":"136","author":"Giamarellos-Bourboulis","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2026012706471128200_ljaf398-B4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41423-018-0024-0","article-title":"NETosis, complement and coagulation: a triangular relationship","volume":"16","author":"de Bont","year":"2019","journal-title":"Cell Mol Immunol"},{"key":"2026012706471128200_ljaf398-B5","first-page":"413","article-title":"Complement activation in hidradenitis suppurativa: a new pathway of pathogenesis?","volume":"179","author":"Kanni","year":"2018","journal-title":"Br J Dermatol"},{"key":"2026012706471128200_ljaf398-B6","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjd.18877","article-title":"Clinical efficacy of complement C5a inhibition in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab","volume":"183","author":"Giamarellos-Bourboulis","year":"2020","journal-title":"Br J Dermatol"},{"key":"2026012706471128200_ljaf398-B7","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"2026012706471128200_ljaf398-B8","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1111\/bjd.15748","article-title":"Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity","volume":"177","author":"Zouboulis","year":"2017","journal-title":"Br J Dermatol"},{"key":"2026012706471128200_ljaf398-B9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa1504370","article-title":"Two phase 3 trials of adalimumab in hidradenitis suppurativa","volume":"375","author":"Kimbal","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012706471128200_ljaf398-B10","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","article-title":"Epithelialized tunnels are source of inflammation in hidradenitis suppurativa","volume":"147","author":"Navrazhina","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"2026012706471128200_ljaf398-B11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/jdv.15183","article-title":"Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from hidradenitis suppurativa lesions","volume":"33","author":"Ardo","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026012706471128200_ljaf398-B12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2020.12.089","article-title":"The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: results of a prospective European cohort study","volume":"85","author":"van Straalen","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2026012706471128200_ljaf398-B13","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1016\/j.jaad.2019.12.044","article-title":"Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: a post hoc analysis of PIONEER 1 and 2 individual patient data","volume":"82","author":"Frew","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2026012706471128200_ljaf398-B14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","article-title":"Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial","volume":"156","author":"Bechara","year":"2021","journal-title":"JAMA Surg"},{"key":"2026012706471128200_ljaf398-B15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1001\/jamadermatol.2021.2905","article-title":"Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa. A phase 2, double-blind, placebo-controlled randomized clinical trial","volume":"157","author":"Glatt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026012706471128200_ljaf398-B16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1001\/jamadermatol.2015.3903","article-title":"Safety and efficacy of anakinra in severe hidradenitis suppurativa: a randomized controlled trial","volume":"152","author":"Tzanetakou","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2026012706471128200_ljaf398-B17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jid.2017.10.030","article-title":"MABp1 targeting IL-1\u03b1 for moderate to severe hidradenitis suppurativa not eligible for adalimumab: a randomized study","volume":"138","author":"Kanni","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2026012706471128200_ljaf398-B18","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1111\/jdv.19252","article-title":"Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study","volume":"37","author":"Kimbal","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2026012706471128200_ljaf398-B19","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","article-title":"Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomized, placebo-controlled, double-blind phase III trials","volume":"404","author":"Kimball","year":"2023","journal-title":"Lancet"},{"key":"2026012706471128200_ljaf398-B20","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","article-title":"Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials","volume":"403","author":"Kimbal","year":"2024","journal-title":"Lancet"},{"key":"2026012706471128200_ljaf398-B21","doi-asserted-by":"crossref","first-page":"EVIDoa2300155","DOI":"10.1056\/EVIDoa2300155","article-title":"Brepocitinib, zimlovisertib and ropsacitinib in hidradenitis suppurativa","volume":"3","author":"Kimball","year":"2024","journal-title":"NEJM Evid"},{"key":"2026012706471128200_ljaf398-B22","doi-asserted-by":"crossref","first-page":"e716","DOI":"10.1111\/jdv.19856","article-title":"Significant spontaneous daily fluctuation of inflammatory nodules and abscesses but not of draining tunnels in hidradenitis suppurativa\/acne inversa","volume":"38","author":"Zouboulis","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf398\/64659377\/ljaf398.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/2\/254\/64659377\/ljaf398.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/2\/254\/64659377\/ljaf398.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T11:47:22Z","timestamp":1769514442000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/2\/254\/8284855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,10,13]]},"published-print":{"date-parts":[[2026,1,27]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf398","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,10,13]]}}}